Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

K Muraoka; K Fujimoto; X Sun; K Yoshioka; K Shimizu; M Yagi; H Bose; I Miyazaki; K Yamamoto

doi:10.1172/JCI118690

Published June 1, 1996 - More info

View PDF

Abstract

FK506 is a powerful immunosuppressive drug currently in use that inhibits the activation of several transcription factors (nuclear factor (NF)-AT and NF-kappaB) critical for T cell activation. We show here that, contrary to the situation in T cells, FK506 activates transcription factor NF-kappaB in nonlymphoid cells such as fibroblasts and renal mesangial cells. We further show that FK506 induces NF-kappaB-regulated IL-6 production in vitro and in vivo, in particular in kidney. IL-6 has been shown previously to produce renal abnormalities in vivo, such as mesangioproliferative glomerulonephritis. Similar renal abnormalities were also observed in FK506-treated animals. These results thus suggest a causal relationship between FK506-induced NF-kappaB activation/IL-6 production and some of FK506-induced renal abnormalities.

Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

K Muraoka, K Fujimoto, X Sun, K Yoshioka, K Shimizu, M Yagi, H Bose Jr, I Miyazaki, and K Yamamoto

Article tools

Metrics

Go to

Immunosuppressant FK506 induces interleukin-6 production through the activation of transcription factor nuclear factor (NF)-kappa(B). Implications for FK506 nephropathy.

K Muraoka, K Fujimoto, X Sun, K Yoshioka, K Shimizu, M Yagi, H Bose Jr, I Miyazaki, and K Yamamoto

Article tools

Metrics

Go to

Sign up for email alerts